Drug Profile
KD 026
Alternative Names: KD026; SLX 4090; SLx-4090Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Surface Logix
- Developer Kadmon Pharmaceuticals
- Class Antihyperglycaemics; Antihyperlipidaemics; Benzamides; Isoquinolines; Obesity therapies; Small molecules
- Mechanism of Action Microsomal triglyceride transfer protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Type 2 diabetes mellitus
- Discontinued Dyslipidaemias; Obesity
Most Recent Events
- 16 Apr 2021 Discontinued - Phase-II for Dyslipidaemias in Germany (PO)
- 16 Apr 2021 Discontinued - Phase-II for Dyslipidaemias in USA (PO)
- 16 Apr 2021 Discontinued - Phase-II for Obesity in USA (PO)